← Human Trials & Peer-Reviewed Studies
Increased levels but preserved diurnal variation of serum leptin in GH-deficient patients: lack of impact of different modes of GH administration.
Plain-language guide to PMID 9678531 (1998): randomized controlled trial of Human Growth Hormone.
Key Facts
- PMID
- 9678531
- Journal
- European journal of endocrinology
- Year
- 1998
- Study type
- Randomized Controlled Trial
- Authors
- Nørrelund H et al. (7 authors)
- DOI
- 10.1530/eje.0.1380644
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Human Growth Hormone, published as a randomized controlled trial.
The regulation of leptin production in humans is poorly understood but appears to depend on total body fat, changes in energy intake and insulin levels.
Since growth hormone (GH) is an important regulator of both lipid metabolism and insulin secretion and action, the researchers tested whether GH status directly or indirectly regulates leptin secretion.
Who Took Part
By PubMed's age tags, the people studied were children, teenagers and adults, both men and women.
Circadian serum leptin concentrations were measured in GH-deficient patients in two different protocols involving different modes of acute and prolonged GH exposure.
How the Study Was Run
The design is described as randomized.
Because people in this Human Growth Hormone study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
What Was Measured
The regulation of leptin production in humans is poorly understood but appears to depend on total body fat, changes in energy intake and insulin levels.
Since growth hormone (GH) is an important regulator of both lipid metabolism and insulin secretion and action, the researchers tested whether GH status directly or indirectly regulates leptin secretion.
PubMed files the paper under topics including Circadian Rhythm, Human Growth Hormone, Leptin, Obesity and Proteins.
What This Means in Plain Language
The paper is a randomized study of Human Growth Hormone.
The publication is from 1998 (European journal of endocrinology), a journal based in England.
More context: the related Exogenous HGH, sermorelin & older GHRPs (why they're passed over) library page, all human trials.
Related Library Page
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.